Participated · Series B · Jun 2026

Dawn Aerospace develops reusable space transportation systems, including the Aurora spaceplane and the Loop in-orbit refueling network. The company plans for the Aurora spaceplane to become the first vehicle to fly twice-daily to the Kármán line in 2027. Its Loop refueling network is targeting an in-orbit demonstration in 2028, and Dawn said it will demonstrate in-orbit refueling of its satellite propulsion systems in 2028. Financially, Dawn recently closed a US$25 million Series B at a $195 million post-money valuation led by Balerion Space Ventures. The company intends to use the Series B proceeds to accelerate global expansion of its reusable space transportation business. No operating metrics or founding year were disclosed in the sourced article.

Participated · Series A · Jun 2026

Foundation Alloy commercializes a solid-state alloying technique that repeatedly smashes metal powders together to create homogeneous alloys that traditional melting processes cannot achieve. The process reportedly uses around an order of magnitude less energy than conventional melting-based alloying and enables combinations of elements with very different melting points. The company has been selling bespoke metals in small batches and is running pilots with customers in automotive, aerospace, semiconductor, defense, luxury watches, and cutlery. Early commercial products include tooling parts for automakers and parts targeted at drone supply chains within defense. Foundation Alloy says it is currently constrained by production capacity rather than demand and plans to scale to several tons per week by 2027 using proceeds from its Series A. Its technology builds on about 20 years of research led by Tim Rupert and Chris Schuh, and the company is led by CEO and co-founder Jake Guglin.

Led · Series C · Jan 2026

Antheia is a biosynthesis company focused on transforming pharmaceutical manufacturing through engineered microorganisms that produce complex active pharmaceutical ingredients (APIs). The firm employs its advanced biosynthesis platform to generate critical drug ingredients domestically, reducing reliance on fragile global supply chains. Under an ongoing collaboration with the U.S. government’s BioMaP-Consortium, Antheia will scale commercial production of two essential pharmaceutical compounds in the United States. The company positions its technology as a solution to longstanding vulnerabilities in healthcare supply chains and aims to build a more resilient, on-shore source of medicines for the American market. To date, Antheia has secured $21 million in federal project investment dedicated to this initiative, including a recent $9 million expansion award. These funds will be deployed to increase manufacturing capacity and accelerate the company’s path to large-scale commercialization. No additional operating metrics or revenue figures were disclosed in the article.

Led · Seed · Sep 2025

Revalia Bio delivers on-demand access to functional, perfused human organs and associated analytics via its Human Data Trials, using proprietary perfusion technology to sustain organs under clinical conditions. Its Human Data Stack unifies perfused-organ data, donor medical histories, and high-resolution digital analytics to produce translatable insight across discovery, safety, biodistribution, and efficacy. The company partners with academic medical centers and organ procurement organizations to repurpose donated, non-transplantable organs for research, enabling donors and families to leave a research legacy. Since launching commercially in 2023, Revalia says it has quadrupled revenue and recently signed two of the world’s top 10 pharmaceutical companies as customers; it has also developed a human lung cancer model and achieved a four-day kidney perfusion protocol. Revalia positions its platform to improve preclinical prediction, reduce development costs, and eliminate risk to living patients by grounding development in real human data. Leadership includes CEO Greg Tietjen and a multidisciplinary team including Jenna DiRito, Kourosh Saeb-Parsy, Peter Buniak, Helen Hughes, and early investor Milad Alucozai, and the company aims to serve as foundational infrastructure for human-centered drug development.

Led · Series A · Jun 2025

Tacta Systems is a Palo Alto-based robotics company developing Dextrous Intelligence, a smart nervous system that gives robots human-level tactile skills and spatial awareness. Its proprietary combination of software, hardware and AI enables robots to sense, adapt, and manipulate the physical world with human-like precision and speed. The company targets industrial and consumer applications, aiming to perform delicate, variable, human-like tasks with flexibility, efficiency and autonomy. Tacta says its technology will help automate factory work and physically grueling labor. Founded by serial entrepreneurs and led by co-founder and CEO Andreas Bibl, the company announced new funding to accelerate development of its robotic solutions.